Long term survival for lung cancer patients improved with new treatment combination, new Irish research reveals
Results from the phase 3 clinical trial were published in the New England Journal of Medicine.
Prof Patrick Forde of the Trinity St James's Cancer Institute (TSJCI), Trinity College Dublin School of Medicine, presented the findings at the American Society of Clinical Oncology Annual Meeting in Chicago, USA, at the weekend.
Prof Forde led the CheckMate 816 trial which enrolled 358 patients globally who were diagnosed with the most common type of lung cancer, non-small cell lung cancer (NSCLC), at a stage where it could be removed by surgery.
However, despite undergoing surgery, 50pc of patients with stage 2 or 3 lung cancer will eventually have relapse of their cancer.
Immunotherapy drugs known as immune checkpoint inhibitors, in particular those that block a receptor called PD-1, have led to improved survival for patients with advanced cancers by unmasking the tumour to the patient's immune system.
However, up until now, no study had shown long-term benefit to this treatment in helping to cure earlier stage lung cancer.
Earlier in his career as an oncologist at Johns Hopkins in the United States Prof Forde led the first clinical trial of immunotherapy prior to surgery (neoadjuvant therapy) for lung cancer which was published in the New England Journal of Medicine in 2018.
That study showed that among 20 patients who underwent surgery after two doses of immunotherapy, almost half had little or no remaining cancer at the time of their operation.
In an earlier report of the CheckMate 816 trial, patients with lung cancer who received immunotherapy along with chemotherapy prior to surgery were more likely to have had their cancer eliminated completely by the time of surgery and also had lower rates of cancer relapse.
Side effects were not increased with the addition of immunotherapy, and in general, surgeries went well.
These findings led to the approval of the neoadjuvant nivolumab plus chemotherapy in several countries globally, including as a standard treatment for eligible patients in Ireland.
In the latest update from the trial, patients who received immunotherapy plus chemotherapy before surgery were approximately 10pc more likely to be alive at five years than those who just received chemotherapy.
Among the 24pc of patients treated with immunotherapy plus chemotherapy who had no cancer remaining at the time of surgery - known as a pathologic complete response - no patient had died from lung cancer by five years.
Prof Forde is also co-leading an international clinical trial open in Ireland at TSJCI, Beaumont, Galway and Mater Hospitals that is aimed at further improving outcomes for patients undergoing surgery.
Results from part of this study were also published this week in the prestigious Nature Medicine journal.
In the NeoCOAST-2 trial, patients who received standard chemo-immunotherapy plus a new treatment called an antibody drug conjugate (ADC) before surgery were more likely to have no viable cancer remaining at the time of surgery, suggesting that this additional treatment could improve outcomes further.
Prof Forde said: 'Immunotherapy has helped many patients with stage 4 lung cancer live longer with good quality of life.
"Until recently we have not had new treatments available that can increase the chances of cure after lung cancer surgery. The use of immunotherapy with chemotherapy before lung cancer surgery has now been shown to reduce the risk of cancer coming back and improve long term survival.
"Cancer clinical trials are key to improving outcomes for patients with cancer and offer the potential for early access to the latest cutting edge cancer treatments. I am delighted to be able to help expand clinical trial options for patients in Ireland.'
In 2024, Prof Forde joined the Trinity St James's Cancer Institute (TSJCI) as the Patrick Prendergast Professor of Clinical Immuno-Oncology.
This position was established by a philanthropic gift from Dr Stanley Quek, Trinity alumnus and former Pro-Chancellor of the University. In collaboration with colleagues across Ireland, Prof Forde's goal is to improve access for patients to cutting edge cancer clinical trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
30-06-2025
- Irish Independent
New breakdown shows just who is getting Wexford council houses – ‘There's a real false narrative out there'
You won't have to look too far online to find allegations that foreign nationals arriving into Ireland are being bumped up the queue for social housing at the expense of Irish people who may have been on the local authority housing list for years. It's something that was put to the Wexford councillor on several occasions, but it simply didn't match with his experience on the ground. Following several requests and follow ups with Wexford County Council's housing section, Cllr Forde obtained figures which provide a breakdown of the local authority's own-build social housing allocation. While the figures don't account for the sizeable chunk of social housing provided by Approved Housing Bodies (AHBs), they do provide a clear pattern in relation to where council houses are going. The figures show that of 3,325 Wexford County Council built houses allocated since 2013, 2,773 (or 83%) went to Irish nationals. The next highest allocation went to people from the EEA (European Economic Area) with 404 (or 12%). Applicants from the UK accounted for 39 allocations (or 1%), while 109 houses (3.3%) were allocated to those from outside of the European Economic Area. It was also pointed out that all of these applicants, over a 12 year period, would have been subject to the same criteria and waiting times. For Cllr Forde, it was important to bust some of the myths circulating online. "I've been looking for these figures for quite a while,' he said. 'There's a narrative out there on social media that foreign nationals are coming into the country and taking social houses and getting them quicker than Irish people. A lot of people have fallen into the trap of believing this. "The figures show that, for the past 12 years, the vast majority of houses have gone to Irish nationals and that reflects my experience on the ground, working with a vast majority of Irish families on housing. ADVERTISEMENT "At the end of the day, foreign nationals are entitled to apply for housing here, as they should be. Many come and contribute greatly to our communities and work hard. They are entitled to apply for housing supports. But they are also held to the same criteria as everybody else.' Cllr Forde noted an influx of people coming from overseas were working their way through the International Protection Accommodation Service (IPAS), but stated this was completely different and had no bearing on social housing allocation. "In Sinn Féin we've called for the IPAS system to be abolished on several occasions,' he said. 'It's not good for the people using the system and the state should be taking the lead rather than it being a cash cow. There's huge money to be made in that system at the moment. I don't think people should be making money of the back of vulnerable people arriving into Ireland.' Returning to the housing allocation figures, Cllr Forde says that the most shocking thing about them was that there were only 3,325 houses allocated over 12 years, although he did conceded that the figures don't include housing provided by AHBs, which accounts for a large chunk of social housing. "I'm waiting on further figures in relation to the breakdown of the allocations from AHBs too,' he said. 'But I would believe that the allocation of houses by AHBs closely mirrors that of Wexford County Council's own-builds. "I think we should be pushing for more Wexford County Council own-builds as well,' he added. 'We need to be more ambitious in that regard and shouldn't be so reliant on AHBs and other developers. We need to start rezoning and identifying land to build houses and be more proactive in that regard." Regardless, Cllr Forde believes that there's a misdirected anger on social media and he hopes that these figures provide some clarity. "The narrative that's out there is false,' he said. 'I'd say the government is very happy with it. It deflects from the real problems – the shortage of housing supply, spiralling cost of living, lack of homeless services. People are venting their anger in the wrong places, aiming it at vulnerable minority groups instead of at the government and government policy. Lack of supply and lack of proper policy is the issue and that's down to the government.'
Irish Independent
19-06-2025
- Irish Independent
Frustration in Galway as opening of Renmore Barracks walkway remains unclear
It has been about three years since Galway City Council started working to open a permeability route to the railway line path from Liam Mellows GAA Club, which would provide a 2.5km vehicle free walkway and cycleway from Eyre Square to Renmore and Ballyloughanne. The path strays onto lands belonging to Dún Uí Mhaelíosa (Renmore Barracks), which led to the Defence Forces closing the pathway over safety grounds, preventing unauthorised access to military property. The walkway in concern is about 150m in length and is situated outside the security walls of the Barracks. Before its closure, this roadway has been used by the public for generations without any restriction. Positive discussions have been going on between Galway City Council, who owns a section of land between Liam Mellow GAA and Renmore Barracks, and representatives from the Renmore Barracks. However, last summer Renmore Barracks informed Galway City Council they objected to this proposal and would not allow the permeability route to proceed. The Army Barracks have also erected a permanent fence around GCC land and gate blocking entry to GCC. So another year has passed, and Fine Gael Councillor for Galway City East Shane Forde explained to the Irish Independent the community's patience is running short. 'I want Fine Gale leader and Minister For Defence Simon Harris to intervene directly to resolve the impasse. The issue locally is affecting hundreds of kids playing sport every day and the community of Galway City East,' he said. Cllr Forde argued the Army Barrack's safety should not be an issue as there is currently a public Pitch N Putt located at the end of the roadway which the barracks allow access to. 'The Pitch N Putt course is open and if national security was the greatest [issue], how come there's no issue with people using the golf course? It's absolute madness. 'We should 100pc address the Army's safety concerns but also highlight the fact that it is an absolute nonsense to say that it's a national security issue but every day 200 or 300 people are playing Pitch N Putt down the golf course every day of the week.' Cllr Forde claimed that talks have fallen again lately after a possible solution, which included the building of a bridge over the railway line, has been rumoured would cost about €1million. 'There was proposals that the defence Forces were looking at to put a bridge over the railway line and then pedestrians would use that bridge over the railway line and onto the Renmore Road. That's what the Defence Forces were looking to see would it be possible. 'But what I've been informed of the past couple of days is that there's talk that that could come to the region of €1 million. That's €1 million of taxpayers money. When we could have this issue resolved [easily]. So now the two parties are back to the drawing board, as Cllr Forde said the initial solution would be 'the fairest proposal to everyone'. He explained: 'They had no issue with [reopening the pathway] until a year ago. 'The reality is, all they have to do is go back to the original proposal where the council will erect the safety fencing, the council will put up the gates, the council will pay for the CCTV, and the barracks will have security that they need. 'If national security is of importance as what the army lead it to believe, why is it that that everyday hundreds of people can use the pitch and putt course at the back of the barracks and the only access way in is through the back of the barracks, on the the same walkway that their closed. 'We've missed a whole summer while this issue was dragging on and we can't get into agreement on it.'
Irish Independent
03-06-2025
- Irish Independent
Long term survival for lung cancer patients improved with new treatment combination, new Irish research reveals
The patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at five years after completing treatment. Results from the phase 3 clinical trial were published in the New England Journal of Medicine. Prof Patrick Forde of the Trinity St James's Cancer Institute (TSJCI), Trinity College Dublin School of Medicine, presented the findings at the American Society of Clinical Oncology Annual Meeting in Chicago, USA, at the weekend. Prof Forde led the CheckMate 816 trial which enrolled 358 patients globally who were diagnosed with the most common type of lung cancer, non-small cell lung cancer (NSCLC), at a stage where it could be removed by surgery. However, despite undergoing surgery, 50pc of patients with stage 2 or 3 lung cancer will eventually have relapse of their cancer. Immunotherapy drugs known as immune checkpoint inhibitors, in particular those that block a receptor called PD-1, have led to improved survival for patients with advanced cancers by unmasking the tumour to the patient's immune system. However, up until now, no study had shown long-term benefit to this treatment in helping to cure earlier stage lung cancer. Earlier in his career as an oncologist at Johns Hopkins in the United States Prof Forde led the first clinical trial of immunotherapy prior to surgery (neoadjuvant therapy) for lung cancer which was published in the New England Journal of Medicine in 2018. That study showed that among 20 patients who underwent surgery after two doses of immunotherapy, almost half had little or no remaining cancer at the time of their operation. In an earlier report of the CheckMate 816 trial, patients with lung cancer who received immunotherapy along with chemotherapy prior to surgery were more likely to have had their cancer eliminated completely by the time of surgery and also had lower rates of cancer relapse. Side effects were not increased with the addition of immunotherapy, and in general, surgeries went well. These findings led to the approval of the neoadjuvant nivolumab plus chemotherapy in several countries globally, including as a standard treatment for eligible patients in Ireland. In the latest update from the trial, patients who received immunotherapy plus chemotherapy before surgery were approximately 10pc more likely to be alive at five years than those who just received chemotherapy. Among the 24pc of patients treated with immunotherapy plus chemotherapy who had no cancer remaining at the time of surgery - known as a pathologic complete response - no patient had died from lung cancer by five years. Prof Forde is also co-leading an international clinical trial open in Ireland at TSJCI, Beaumont, Galway and Mater Hospitals that is aimed at further improving outcomes for patients undergoing surgery. Results from part of this study were also published this week in the prestigious Nature Medicine journal. In the NeoCOAST-2 trial, patients who received standard chemo-immunotherapy plus a new treatment called an antibody drug conjugate (ADC) before surgery were more likely to have no viable cancer remaining at the time of surgery, suggesting that this additional treatment could improve outcomes further. Prof Forde said: 'Immunotherapy has helped many patients with stage 4 lung cancer live longer with good quality of life. "Until recently we have not had new treatments available that can increase the chances of cure after lung cancer surgery. The use of immunotherapy with chemotherapy before lung cancer surgery has now been shown to reduce the risk of cancer coming back and improve long term survival. "Cancer clinical trials are key to improving outcomes for patients with cancer and offer the potential for early access to the latest cutting edge cancer treatments. I am delighted to be able to help expand clinical trial options for patients in Ireland.' In 2024, Prof Forde joined the Trinity St James's Cancer Institute (TSJCI) as the Patrick Prendergast Professor of Clinical Immuno-Oncology. This position was established by a philanthropic gift from Dr Stanley Quek, Trinity alumnus and former Pro-Chancellor of the University. In collaboration with colleagues across Ireland, Prof Forde's goal is to improve access for patients to cutting edge cancer clinical trials.
